Special Issue "Pharmaceutical Nanotechnology"
A special issue of Nanomaterials (ISSN 2079-4991).
Deadline for manuscript submissions: 31 October 2018
Prof. Dr. Erem Bilensoy
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
Website | E-Mail
Interests: Tumor targeted nanoparticles; Cyclodextrin based nanocarriers (nanoparticles, nanocapsules, nanofibers, hydronanogels); Amphiphilic cyclodextrins ; Cationic nanoparticulate drug delivery systems; Wound healing; Bioavailability enhancement through cyclodextrin complexation; Inkjet and 3D printed drug delivery systems
Pharmaceutical nanotechnologies, over the past twenty years, have shown great potential for drug delivery due to their unique biopharmaceutical properties. The first breakthrough applications were related to the intravenous administration of anticancer drugs, loaded liposomes, opening the possibility to target tumor parenchyma via the enhanced-permeability and retention effect. However, more recently, the development of manufactured nanocarriers, starting from different materials, and with more or less complex surface modifications, has widened the possibilities of drug-loaded nanoparticles, allowing for administration via different administration routes, stimuli or environment responsive drug delivery, active targeting of organs or specific cells and multiple actions, as in the case of theranostics.
This Special Issue of Nanomaterials will attempt to cover recent advances in Pharmaceutical Nanotechnologies for drug delivery, including biodegradable, surface-modified, stimuli-responsive or targeted nanoparticles, liposomes, and micelles designed for parenteral or non-parenteral administration routes.
Prof. Dr. Fabio Sonvico
Prof. Dr. Erem Bilensoy
Prof. Dr. Adriana Raffin Pohlmann
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- parenteral administration
- oral delivery
- nasal delivery
- pulmonary delivery
- topical delivery
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Biocompatible nanostructured materials for cancer diagnostic and therapy
Authors: Tina Mavrič 1,3, Metka Benčina 2, Roghayeh Imani 1, Ita Junkar 2, Damjana Drobne 4, Veronika Kralj-Iglič 3 , Aleš Iglič 1
Affiliations: 1 Laboratory of Biophysics, Faculty of Electrical Engineering, University of Ljubljana, Tržaška 25, SI-1000 Ljubljana, Slovenia
2 Jožef Stefan Institute, Jamova 39, SI-1000 Ljubljana, Slovenia
3 Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Zdravstvena 5, SI-1000 Ljubljana, Slovenia
4 Bionanoteam, Biotechnical Faculty, University of Ljubljana, Jamnikarjeva 101,SI-1000 Ljubljana
Abstract: Cancer incidence is on the rise worldwide, according to estimates the cancer related deaths will rise for over 20% in this decade alone. Together with early detection of the disease, a point of care and low invasive treatment method, as opposed to the current severe side effect associated procedures of radio and chemotherapy treatments, is severely needed to act effectively toward the burden of cancer. In the current work we encompass the nanostructures applicable for cancer diagnostics and therapy, the nanodomain approaches being developed on this field to push the frontiers toward clinical trials and overview of the cooperation of nanostructures with oncology-focused pharmaceuticals and the drug-free nanotechnology for cancer treatment. In this regard we will also highlight the resounding achievement of our lab regarding gadolinium-enriched TiO2 microspheres. This material may as well be on the forefront of cancer treatment because it is praised for the biocompatibility, and represents a state of the art possibility of its simultaneous use for cancer diagnosis by using MRI, as well as treatment through ROS production upon UV irradiation.
Title: Drug delivery system for emodin based on mesoporous silica SBA-15
Authors: Tamara Krajnović, Danijela Maksimović-Ivanić, Sanja Mijatović, Dijana Drača, Katharina Wolf, David Edeler, Ludger A. Wessjohann and Goran N. Kaluđerović*
Abstract: In this study mesoporous silica SBA-15 was evaluated as a vehicle for the transport of the cytotoxic natural product emodin (EO). SBA-15 was loaded with different quantities of EO (SBA-15|EO1-SBA-15|EO5: 8-36 %) and characterized by traditional methods. Several parameters (stabilities) and the in vitro behavior on tumor cell lines (melanoma A375, B16 and B16F10) were investigated. SBA-15 suppresses EO release in acidic milieu, pointing out that EO will not be discharged in the stomach. Furthermore, SBA-15 protects EO from photodecomposition. In vitro studies showed a dose dependent decrease of cellular viability which is directly correlated with an increasing amount of EO in SBA-15 for up to 27 % of EO, while a constant activity for 32 % and 36 % of EO in SBA-15 was observed. Additionally, SBA-15 loaded with EO (SBA-15|EO3) does not disturb viability of peritoneal macrophages. SBA-15|EO3 causes inhibition of tumor cell proliferation and triggers apoptosis, connected with caspase activation, upregulation of Bax, as well as Bcl-2 and Bim downregulation along with amplification of PARP fragmentation. Thus, the mesoporous SBA-15 is a promising carrier of the water-insoluble drug emodin.
Title: Lipid-based nanoparticles as a potential drug delivery approach in the treatment of rheumatoid arthritis
Author: Jia-You Fang
Abstract: Rheumatoid arthritis (RA), a chronic and joint-related autoimmune disease, results in immune dysfunction and destruction of joints and cartilages. Small molecules and biologic therapies have been applied in a wide variety of inflammatory disorders, but theirs utility as a therapeutic agent is limited by its poor absorption, rapid metabolism and serious side effects. To improve these limitations, nanoparticles, as drug delivery systems, are capable of encapsulating and protecting drugs from degradation before to reaching target site in vivo. The present researches purpose a platform for different lipid nanoparticles approaches for RA therapy, taking advantage of the new emerging field of lipid nanoparticles to develop a targeted theranostic system for in vivo administration in RA. This review aims at providing that the recent major applications of lipid nanoparticle, a biocompatible and biodegradable delivery system, effectively improve targeting over free drugs via presentation of tissue-specific targeting ligands and offer controlled drug release by altering nanoparticle composition in RA.
Tentative Title: Cabazitaxel loaded electrospinning nanofibers for in situ glioma therapy
Author: Gang Guo
Affiliation: State Key Laboratory of Biotherapy and Cancer Center, Sichuan University
Abstract: Gliomas are the most common tumors in the central nervous system, of which the prognosis is exactly poor. The efficacy of conventional therapeutic methods including surgical removal, radiation therapy and chemotherapy is weakened due to the recurrence of the tumors. Surgical removal is infeasible because of the tumor size and the tumor location, which leads to high mortality of gliomas. On the contrary, the localized drug delivery is a safer and more efficient strategy due to the sustained drug release and reduced drug toxicity. Cabazitaxel (CBZ), a next-generation taxane for the treatment of hormone-refractory prostate cancer, has been proved that can penetrate blood-brain barrier (BBB) and shows potentials for inhibiting tumors in the central nervous system (CNS). In this study, we prepared CBZ loaded nanofibers consisted of PPC and modified chitosan (CS). Chitosan presents bioactivities of antioxidancy, antimicobes and immunocompetence, but its application is hampered by the poor solubility. PDLLA side chains were grafted to chitosan, which broke the intermolecular bonds hence remarkably improved solubility of CS in common organic solvents. The anti-tumor effects of the nanofibers were evaluated ex vivo and in vivo. Annexin V/PI analysis, immunohistochemistry staining (IHC) and TUNEL results confirmed that the CBZ loaded PPC/GTCS mats inhibited the growth of glioma by inhibiting the proliferation and triggering the apoptosis of tumor cells. The CBZ loaded nanofibers showed great potent for the treatment of glioma.
Title: Cationic liposomes carrying siRNA: impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape
Authors: Anna Lechanteur 1, Vincent Sanna 1, Amandine Duchemin 2, Brigitte Evrard 1, Denis Mottet 2, Géraldine Piel 1
1 Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liège, Liège (4000), Belgium
2 Laboratory of Protein Signaling and Interactions, GIGA-Molecular Biology of Diseases, University of Liège, Liège (4000), Belgium
Correspondence: Anna Lechanteur, PhD, ULiege Laboratoire de Technologie Pharmaceutique et Biopharmacie, CHU Bat B36 Tour 4, 1 avenue de l'Hopital, 4000 Liège, Belgium
Phone number: +32 4 366 43 06
Fax: +32 4 366 43 02
Abstract: In recent year, cationic liposomes have gained a lot of attention for siRNA delivery. Despite this, intracellular barriers as endosomal escape and cytosolic delivery of siRNA are still hurdles as well as the cytotoxicity due to cationic lipids. To address these issues, we developed four liposomal formulations composed of two different cationic lipids (DOTAP and DC-Cholesterol) and different ratio of co-lipids (cholesterol and DOPE). The objective is to dissect these impacts on siRNA efficacy and on cytotoxicity. Liposomes were complexed to siRNA at six different N/P molar ratios, physico-chemical properties were characterized and consequently N/P 2.5, 5 and 10 were selected for in vitro experiments. We have shown that the cytotoxicity is influenced by the N/P ratio, the concentration of cationic lipid as well as the nature of the cationic lipid. For instance, cell viability decreased of 70% with liposomes DOTAP/Cholesterol/DOPE 1/0.75/0.5 used at a N/P ratio of 10 whereas the same formulation at a N/P ratio of 2.5 was safe. Interestingly, we have observed difference in terms of mRNA knock-down efficiency whereas the transfection rate was quite similar for each formulation. Liposomes containing 50% of DOPE induced a mRNA extinction of around 80%. This study allowed to highlight crucial parameters in order to develop lipoplexes which are safe and induce an efficient intracytoplasmic release of siRNA.
Title: Development of nano-delivery systems for the delivery and targeting of oncolytic adenoviruses
Abstract: In recent years, oncolytic adenoviruses have been used as anticancer agents and attracting increasing interest in cancer gene therapy due to the selective infection and replication in tumor cells. However, the applications of oncolytic adenovirus are limited by immunogenicity, rapid clearance from blood stream and also reduce adhesion to cell membranes. Cationic polymers and liposomes can efficiently encapsulate the adenovirus by forming the electrostatic force with the surface negative chargers of adenovirus to overcome the limitations and also improve the therapeutic efficacy. In this paper, cationic DOPE/DC-CHOL liposomes and three different cationic polymers: poly (ethylenimine), poly(L-lysine) and DEAE-Dextran were applied as nano-delivery systems for prostate specific oncolytic adenovirus to achieve prostate targeted gene therapy by in vitro and in vivo.